JP2011152137A5 - - Google Patents

Download PDF

Info

Publication number
JP2011152137A5
JP2011152137A5 JP2011045589A JP2011045589A JP2011152137A5 JP 2011152137 A5 JP2011152137 A5 JP 2011152137A5 JP 2011045589 A JP2011045589 A JP 2011045589A JP 2011045589 A JP2011045589 A JP 2011045589A JP 2011152137 A5 JP2011152137 A5 JP 2011152137A5
Authority
JP
Japan
Prior art keywords
nucleic acid
acid molecule
hpv45
protein
yeast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011045589A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011152137A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011152137A publication Critical patent/JP2011152137A/ja
Publication of JP2011152137A5 publication Critical patent/JP2011152137A5/ja
Pending legal-status Critical Current

Links

JP2011045589A 2003-09-29 2011-03-02 酵母におけるhpv45l1の最適化された発現 Pending JP2011152137A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50681203P 2003-09-29 2003-09-29
US60/506,812 2003-09-29

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006528190A Division JP5451960B2 (ja) 2003-09-29 2004-09-24 酵母におけるhpv45l1の最適化された発現

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014129350A Division JP2014221052A (ja) 2003-09-29 2014-06-24 酵母におけるhpv45l1の最適化された発現

Publications (2)

Publication Number Publication Date
JP2011152137A JP2011152137A (ja) 2011-08-11
JP2011152137A5 true JP2011152137A5 (enExample) 2013-04-04

Family

ID=34421558

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2006528190A Expired - Lifetime JP5451960B2 (ja) 2003-09-29 2004-09-24 酵母におけるhpv45l1の最適化された発現
JP2011045589A Pending JP2011152137A (ja) 2003-09-29 2011-03-02 酵母におけるhpv45l1の最適化された発現
JP2014129350A Pending JP2014221052A (ja) 2003-09-29 2014-06-24 酵母におけるhpv45l1の最適化された発現
JP2016019712A Pending JP2016136947A (ja) 2003-09-29 2016-02-04 酵母におけるhpv45l1の最適化された発現

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2006528190A Expired - Lifetime JP5451960B2 (ja) 2003-09-29 2004-09-24 酵母におけるhpv45l1の最適化された発現

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014129350A Pending JP2014221052A (ja) 2003-09-29 2014-06-24 酵母におけるhpv45l1の最適化された発現
JP2016019712A Pending JP2016136947A (ja) 2003-09-29 2016-02-04 酵母におけるhpv45l1の最適化された発現

Country Status (33)

Country Link
US (2) US7250170B2 (enExample)
EP (1) EP1673106B1 (enExample)
JP (4) JP5451960B2 (enExample)
KR (1) KR101165278B1 (enExample)
CN (1) CN1859923B (enExample)
AR (2) AR045804A1 (enExample)
AT (1) ATE435029T1 (enExample)
AU (1) AU2004277934B2 (enExample)
BE (1) BE2015C072I2 (enExample)
BR (1) BRPI0414845B8 (enExample)
CA (1) CA2539168C (enExample)
CY (2) CY1110525T1 (enExample)
DE (1) DE602004021828D1 (enExample)
DK (1) DK1673106T3 (enExample)
ES (1) ES2327530T3 (enExample)
FR (1) FR15C0083I2 (enExample)
HU (1) HUS1500063I1 (enExample)
IL (1) IL174458A (enExample)
IS (1) IS2694B (enExample)
LT (2) LTC1673106I2 (enExample)
LU (1) LU92902I2 (enExample)
MX (1) MXPA06003457A (enExample)
MY (1) MY140664A (enExample)
NL (1) NL300776I2 (enExample)
NO (3) NO339932B1 (enExample)
NZ (1) NZ545834A (enExample)
PL (1) PL1673106T3 (enExample)
PT (1) PT1673106E (enExample)
RU (1) RU2360001C2 (enExample)
SI (1) SI1673106T1 (enExample)
TW (1) TWI350853B (enExample)
WO (1) WO2005032586A1 (enExample)
ZA (1) ZA200601961B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
MY139500A (en) 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
ES2343255T3 (es) 2004-03-24 2010-07-27 MERCK SHARP & DOHME CORP. Expresion optimizada del vph 52 l1 en levadura.
US7758866B2 (en) 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
CA2604909A1 (en) 2005-04-15 2006-10-26 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
EP1877086A2 (en) * 2005-04-26 2008-01-16 GlaxoSmithKline Biologicals SA Vaccine
KR100904844B1 (ko) * 2006-08-28 2009-06-25 성균관대학교산학협력단 인유두종 바이러스(hpv)유전자를 포함하는자궁경부암의 치료 또는 예방용 dna 백신
WO2008112125A1 (en) * 2007-03-09 2008-09-18 Merck & Co., Inc. Papillomavirus vaccine compositions
MY182347A (en) * 2007-11-23 2021-01-20 Shanghai Zerun Biotechnology Co Ltd Genes encoding major capsid protein l1 of human papilloma virus and use of the same
AU2009348078B2 (en) 2009-06-19 2013-03-14 Eyegene Inc. Vaccine for cervical cancer
EP2576840B1 (en) 2010-05-25 2018-10-17 QIAGEN Gaithersburg, Inc. Fast results hybrid capture assay and associated strategically-truncated probes
EP2722389B1 (en) 2011-06-15 2018-03-07 Hong Jin Kim Method for enhancing the production yield of human papillomavirus l1 protein
WO2012177970A1 (en) 2011-06-24 2012-12-27 Merck Sharp & Dohme Corp. Hpv vaccine formulations comprising aluminum adjuvant and methods of producing same
CN109321592A (zh) * 2012-01-21 2019-02-12 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv18 l1蛋白的方法
CN108624614A (zh) * 2012-03-28 2018-10-09 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv11 l1蛋白的方法
CN110484554B (zh) * 2013-04-26 2024-04-16 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv52 l1蛋白的方法
CN104120088B (zh) * 2013-04-26 2019-09-24 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv58 l1蛋白的方法
CN110295190A (zh) * 2013-05-17 2019-10-01 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv45 l1蛋白的方法
CN112280792B (zh) * 2013-09-29 2022-06-24 上海泽润生物科技有限公司 人乳头瘤病毒基因,及载体,菌株,表达方法
EP3057612B1 (en) 2013-10-16 2020-05-06 Merck Sharp & Dohme Corp. Method of obtaining thermostable dried vaccine formulations
EA201790365A1 (ru) * 2014-09-11 2017-07-31 Кадила Хелзкэр Лимитед Антигены вируса папилломы человека с хорошими иммунологическими свойствами и содержащая их вакцина
CN106282278B (zh) * 2015-06-29 2021-06-08 广东东阳光药业有限公司 一种人乳头瘤病毒l1蛋白的发酵方法
CN106701798B (zh) * 2015-08-12 2021-09-17 北京康乐卫士生物技术股份有限公司 45型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN109750050B (zh) * 2017-11-07 2023-08-18 上海泽润生物科技有限公司 重组人乳头瘤病毒45亚型蛋白表达
US11638754B2 (en) 2020-02-14 2023-05-02 Merck Sharp & Dohme Llc HPV vaccine
CN112680462B (zh) * 2020-12-29 2022-02-22 上海博唯生物科技有限公司 一种人乳头瘤病毒35型/hpv35型l1/l2及其制备与应用
CN113073105B (zh) * 2021-03-23 2023-06-13 重庆博唯佰泰生物制药有限公司 一种表达hpv 56l1的多核苷酸序列及其表达载体、宿主细胞和应用
US20230048144A1 (en) 2021-08-06 2023-02-16 Merck Sharp & Dohme Llc Hpv vaccine
MX2024002144A (es) 2021-08-19 2024-04-23 Merck Sharp & Dohme Llc Nueva nanoparticula lipidica termostable y metodos de uso de la misma.
TW202513091A (zh) 2023-06-09 2025-04-01 美商默沙東有限責任公司 用於人類乳突病毒疫苗之奈米乳液佐劑組合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9507657A (pt) * 1994-05-16 1997-09-09 Merck & Co Inc Proteina isolada e purificada de papilomavirus recombinante capsideos particulas semelhantes a virus processos a virus processos para produzir a proteina para tratar ou prevenir a infecçao por papilomavirus para produzir uma proteina de capsideo de papilomavirus recombinante montada em um capsideo ou particula semelhante a virus e para induzir uma resposta imune em um animal vertebrado composiçoes farmacêuticas kit para a detecçao de papilomavirus ou anticorpos para papilomavirus e sistema sinte
AR004464A1 (es) * 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
JP2001512308A (ja) 1997-02-07 2001-08-21 メルク エンド カンパニー インコーポレーテッド 合成hiv gag遺伝子
EP1015612B1 (en) * 1997-05-27 2005-01-26 Hanil Synthetic Fiber Co., Ltd. Process for preparing recombinant proteins using highly efficient expression vector from saccharomyces cerevisiae
EP1002091B1 (en) 1997-07-09 2012-02-29 Coridon Pty Limited Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue
US6991795B1 (en) * 1998-08-14 2006-01-31 Merck & Co., Inc. Protein delivery system using human papillomavirus virus-like particles
PL347472A1 (en) * 1998-08-14 2002-04-08 Merck & Co Inc Process for purifying human papillomavirus virus-like particles
ATE344052T1 (de) * 1998-08-14 2006-11-15 Merck & Co Inc Protein-verabreichungssystem, das dem menschlichen papillomavirus ähnliche partikel benützt.
DE69924007T2 (de) * 1998-12-23 2006-04-06 Merck & Co., Inc. Neutralsierungs-assay, das humane papillomavirus-ähnliche partikel verwendet
WO2001014416A2 (en) 1999-08-25 2001-03-01 Merck & Co., Inc. Synthetic papillomavirus genes optimized for expression in human cells
US6436402B1 (en) * 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
PT1301614E (pt) 2000-07-21 2007-02-28 Group Limited Glaxo Sequências de codão optimizado do vírus do papiloma
WO2003068163A2 (en) * 2002-02-14 2003-08-21 Novavax, Inc. Optimization of gene sequences of chimeric virus-like particles for expression in insect cells
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
CA2519112C (en) 2003-03-24 2012-09-11 Merck & Co., Inc. Optimized expression of hpv 31 l1 in yeast

Similar Documents

Publication Publication Date Title
JP2011152137A5 (enExample)
JP2014221052A5 (enExample)
Çelik et al. Production of recombinant proteins by yeast cells
JP2013533745A5 (enExample)
JP2011507532A5 (enExample)
CA2539168A1 (en) Optimized expression of hpv 45 l1 in yeast
CA2543928A1 (en) Optimized expression of hpv 58 l1 in yeast
RU2005132603A (ru) Оптимизированная экспрессия hpv 31 l1 в дрожжах
EP3199545A3 (en) Computationally optimized broadly reactive antigens for h1n1 influenza
RU2006137363A (ru) Оптимизированная экспрессия hpv 52 l1 в дрожжах
HRP20160207T1 (hr) Prokariotska ksiloza izomeraza za konstrukciju kvasaca koji fermentiraju ksilozu
JP2010533737A5 (enExample)
JP2015521848A5 (enExample)
JP2012140448A5 (enExample)
JP2014508541A5 (enExample)
RU2017101446A (ru) Получение ксилита из глюкозы при помощи рекомбинантного штамма
RU2012122166A (ru) Способы получения рекомбинантных белков с увеличенными эффективностями секреции
JP2017500024A5 (enExample)
JP2007507207A5 (enExample)
CN102409003A (zh) 多拷贝高效表达重组菌丝霉素的毕赤酵母
JP2016513457A5 (enExample)
JP2021520836A5 (enExample)
CN103834582B (zh) 一种提高衣康酸发酵产量的菌株及其构建和利用菌株生产衣康酸的方法
CN104404057A (zh) 一种大鲵虹彩病毒病疫苗及制备方法和应用
CN104087522B (zh) 一种外源表达甲酸脱氢酶的酵母工程菌及其构建方法和应用